Developing innovative new ways to treat diseases in people and animals.
HylaPharm has a novel drug-delivery technology that makes treatment of certain types of cancer, including breast cancer and head and neck cancer, both safer and more effective in animal trials. Using their new delivery system, chemotherapy drugs can be given as a simple shot which is easier to administer than intravenous infusions, and can even be taken at home. Efficacy has already been demonstrated in animal models in numerous peer-reviewed scientific publications in top journals. Larger animal trials for submission to the US drug regulatory agency (FDA) are underway at Colorado State University Animal Cancer Center. The next step is treating human cancers with HylaPharm drugs. HylaPharm plans to develop its pathway for human trials both in the U.S. as well as internationally. The management team at HylaPharm is well-prepared to advance their drug development commercialization portfolio drawing on their many combined years of experience in cancer drug research, clinical cancer treatment, and healthcare business strategy and management.
We are currently seeking dogs for our Columbia, Missouri animal cancer clinical trials.